| NCT ID | NCT03221426 |
| Title | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies |
Capecitabine + Cisplatin + Pembrolizumab |
| Age Groups: | adult senior |